E-resources
Peer reviewed
-
JANKOVIC, J; HUNTER, C; SINGER, C; STACY, M; TARSY, D; ATASSI, M. Z; DOLIMBEK, B. Z; DOLIMBEK, G. S; ADLER, C. H; BRASHEAR, A; COMELLA, C. L; GORDON, M; RILEY, D. E; SETHI, K
Neurology, 12/2006, Volume: 67, Issue: 12Journal Article
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
